TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 26490328.
- Also identified by DOI 10.1093/brain/awv297 and PMC identifier 4840550.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Currently there is no neuroprotective or neurorestorative therapy for Parkinson's disease. Here we report that transient receptor potential vanilloid 1 (TRPV1) on astrocytes mediates endogenous production of ciliary neurotrophic factor (CNTF), which prevents the active degeneration of dopamine neurons and leads to behavioural recovery through CNTF receptor alpha (CNTFRα) on nigral dopamine neurons in both the MPP(+)-lesioned or adeno-associated virus α-synuclein rat models of Parkinson's disease. Western blot and immunohistochemical analysis of human post-mortem substantia nigra from Parkinson's disease suggests that this endogenous neuroprotective system (TRPV1 and CNTF on astrocytes, and CNTFRα on dopamine neurons) might have relevance to human Parkinson's disease. Our results suggest that activation of astrocytic TRPV1 activates endogenous neuroprotective machinery in vivo and that it is a novel therapeutic target for the treatment of Parkinson's disease.
Medical subject headings
- Astrocytes
- Ciliary Neurotrophic Factor
- Dopaminergic Neurons
- Neuroprotection
- Parkinson Disease
- Substantia Nigra